Synthesis, Molecular Docking and Anticancer Activity of Novel 1,3-Thiazolidin-4-Ones

Abstract

Background: Cancer is a major cause of death all over the globe. Controlling cell division by inhibition of mitosis is the most successful clinical strategy for cancer treatment. The development of novel anticancer agents is the most important area in medicinal chemistry and drug discovery research. Thiazolidine is the multifunctional nucleus which shows a number of pharmacological activities like anticancer, anti-inflammatory, antioxidant, antibacterial, antifungal, antidiabetic, antihyperlipidemic and antiarthritic. Methods: In a present study series of 2-substituted-3-(1H-benzimidazole-2-yl)-thiazolidin-4-ones were designed, synthesized by the microwave-assisted system, and characterized by melting point, IR, 1H NMR, and mass spectroscopy. All the newly synthesized compounds were examined for their in vitro anticancer activity against breast cancer cell line MCF-7 by Sulforhodamine B (SRB) assay. Results: The compounds AB-12 (GI50: 28.5 µg/ml) and AB-6 (GI50: 50.7 µg/ml) exhibited significant cell growth inhibitory activity. Conclusion: These results indicate that compound AB-12 and AB-6 as related polo-like kinase 1inhibitors compounds could be lead compounds for further development of anticancer agents.